产品
编 号：F064699
分子式：C26H28N4O3
分子量：444.53
分子式：C26H28N4O3
分子量：444.53
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1190389-15-1
产品详情
生物活性：
Vibegron (MK-4618) is a potent, highly selective and orally active β3-adrenoceptor agonist (EC50=1.1 nM). Vibegron can be used for severe urgency urinary incontinence related to overactive bladder.
体内研究：
Vibegron (1~12 μΜ; i.v.) exhibits dose dependent decreases in micturition pressure and increases in functional bladder capacity.Vibegron (30 mg/kg; p.o.; 4 weeks) upregulates mRNA levels of type 1, type 3 collagen, TGF‐β1, and HIF‐1α.Vibegron (1 and 10 mg/kg; i.v.; interval 30 minutes) (10 mg/kg) in oxo-M-treated rats makes bladder capacity significantly decreased compared with oxo-M-not treated rats (intravesical instillation of vehicle).Animal Model:Rat
Dosage:1~12 μΜ
Administration:I.v.
Result:Exhibited dose dependent decreases in micturition pressure and increases in functional bladder capacity.
Animal Model:Female C57BL/6N mice (9 weeks old)
Dosage:30 mg/kg
Administration:P.o.; 4 weeks
Result:Upregulated mRNA levels of type 1, type 3 collagen, TGF‐β1, and HIF‐1α at 4 weeks.
Animal Model:Female F344 rats (120–160 g)
Dosage:1 and 10 mg/kg
Administration:I.v.; Interval 30 minutes
Result:Vibegron (10 mg/kg) in oxo-M-treated rats made bladder capacity significantly decreased compared with oxo-M-not treated rats (intravesical instillation of vehicle).
Vibegron (MK-4618) is a potent, highly selective and orally active β3-adrenoceptor agonist (EC50=1.1 nM). Vibegron can be used for severe urgency urinary incontinence related to overactive bladder.
体内研究：
Vibegron (1~12 μΜ; i.v.) exhibits dose dependent decreases in micturition pressure and increases in functional bladder capacity.Vibegron (30 mg/kg; p.o.; 4 weeks) upregulates mRNA levels of type 1, type 3 collagen, TGF‐β1, and HIF‐1α.Vibegron (1 and 10 mg/kg; i.v.; interval 30 minutes) (10 mg/kg) in oxo-M-treated rats makes bladder capacity significantly decreased compared with oxo-M-not treated rats (intravesical instillation of vehicle).Animal Model:Rat
Dosage:1~12 μΜ
Administration:I.v.
Result:Exhibited dose dependent decreases in micturition pressure and increases in functional bladder capacity.
Animal Model:Female C57BL/6N mice (9 weeks old)
Dosage:30 mg/kg
Administration:P.o.; 4 weeks
Result:Upregulated mRNA levels of type 1, type 3 collagen, TGF‐β1, and HIF‐1α at 4 weeks.
Animal Model:Female F344 rats (120–160 g)
Dosage:1 and 10 mg/kg
Administration:I.v.; Interval 30 minutes
Result:Vibegron (10 mg/kg) in oxo-M-treated rats made bladder capacity significantly decreased compared with oxo-M-not treated rats (intravesical instillation of vehicle).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备